Agenda
Cincinnati Children's Hospital
Institutional Biosafety Committee

Meeting Information	
Location:	Virtual
Date and Time:	August 12, 2025 7:30 AM
End Time:	8:47 AM
Chair:	Stephen Waggoner

Attendance	
Name	**Status**
Buddy Goose	Community Member
Brenna Carey	Member Scientist
Bryan Donnelly	Member Scientist
Marcia Espinola	Member Scientist – Non Affiliate
James Gulick	Member Scientist
Scott Keely	Community Member
Ian Lewkowich	Member Scientist – Vice Chair
Tamara Rausch	Member Scientist - BSO
Karnail Singh	Member Scientist
Debbie Slovut	Community Member
Sherry Thornton	Member Scientist
Stephen Waggoner	Member Scientist – Chair
Patrick Reily	Non-voting Member
Rathi Kavanaugh	Non-voting Member
Tabitha Dowdy	Biosafety Office
Courtney Roher	Biosafety Office
Quorum	7
Voting	12

Minutes from Previous Meeting

07.08.25. Minutes.docx(0.01)

The meeting minutes from July 2025 were not approved due to omitted BSL details on each protocol.

Expedited Protocols

Study ID	PI	Reviewer
None		

HRS Amendments

PI:	Sing Sing Way		
Study ID:	Amendment for IBC2024-0033		
Title:	Immunology of Infection, Pregnancy and Aging		
Biosafety Items:	DAPTM		
Modification:	New Agents: Citrobacter rodentium; Citrobacter koseri; Yersinia enterocolitica; Pseudmonas aeruginosa, Enterobacter cloacae		
Primary Reviewer:	Tamara Rausch		
Agents:	Citrobacter rodentium Citrobacter koseri Yersinia enterocolitica Pseudmonas aeruginosa Enterobacter cloacae		
BSL:	2		
Applicable NIH Guidelines:	*Section III-D-1-a* Experiments involving the introduction of recombinant or synthetic nucleic acid molecules into Risk Group 2 agents will usually be conducted at Biosafety Level (BL) 2 containment *Section III-D-7* Experiments Involving Influenza Viruses		
Motion:	Modifications Required		
Vote:	**Yes:** 11	**No:** 0	**Abstain:** 0
	Recuse: 0	**Absent:** 1	

HRS Protocols

PI:	Diego Fernandez
Study ID:	IBC2025-0038
Title:	Melanopsin in mammalian physiology
Biosafety Items:	DVT
Action:	New
Primary Reviewer:	Ian Lewkowich
Secondary Reviewer:	Stephen Waggoner
Agents:	Cholera Toxin Adeno-Associated Virus
BSL:	1
Applicable NIH Guidelines:	*Section III-D* Experiments that Require Institutional Biosafety Committee Approval Before Initiation *Section III-D-4-a* Recombinant or synthetic nucleic acid molecules, or DNA or RNA molecules derived therefrom, from any source except for greater than two-thirds of eukaryotic viral

	genome may be transferred to any non-human vertebrate or any invertebrate organism and propagated under conditions of physical containment comparable to BL1 or BL1-N and appropriate to the organism under study. Animals that contain sequences from viral vectors, which do not lead to transmissible infection either directly or indirectly as a result of complementation or recombination in animals, may be propagated under conditions of physical containment comparable to BL1 or BL1-N and appropriate to the organism under study *Section III-D-4-b* For experiments involving recombinant or synthetic nucleic acid molecules, or DNA or RNA derived therefrom, involving whole animals, including transgenic animals, and not covered by Section III-D-1 or Section III-D-4-a, the appropriate containment shall be determined by the Institutional Biosafety Committee. Experiments involving gene drive modified animals generated by recombinant or synthetic nucleic acid molecules shall be conducted at a minimum of BL2 or BL2-N		
Motion:	Modifications Required		
Vote:	**Yes:** 12	**No:** 0	**Abstain:** 0
	Recuse: 0	**Absent:** 0	

PI:	Olivia Majer
Study ID:	IBC2025-0048
Title:	Innate Immune Regulation
Biosafety Items:	DAVM
Action:	New
Primary Reviewer:	Tamara Rausch
Secondary Reviewer:	Sherry Thornton
Agents:	293T BlaER1 CAL-1 HELA SW1222 THP-1 Lentivirus Murine stem cell virus (Retrovirus)
BSL:	2
Applicable NIH Guidelines:	*Section III-D-1* Experiments Using Risk Group 2, Risk Group 3, Risk Group 4, or Restricted Agents as Host-Vector Systems *Section III-D-1-a* Experiments involving the introduction of recombinant or synthetic nucleic acid molecules into Risk Group 2 agents will usually be conducted at Biosafety Level (BL) 2 containment *Section III-D-3* Experiments Involving the Use of Infectious DNA or RNA Viruses or Defective DNA or RNA Viruses in the Presence of a Helper System in Tissue Culture Systems

	Section III-D-3-a Experiments involving the use of infectious or defective Risk Group 2 viruses in the presence of a helper system may be conducted at BL2 *Section III-D-4* Experiments Involving Whole Animals *Section III-E* Experiments that Require Institutional Biosafety Committee Notice Simultaneous with Initiation *Section III-E-1* Experiments Involving the Formation of Recombinant or Synthetic Nucleic Acid Molecules Containing No More than Two-Thirds of the Genome of any Eukaryotic Virus *Section III-E-3* Experiments Involving Transgenic Rodents *Section III-E-3-a* Experiments involving the breeding of certain BL1 transgenic rodents are exempt under Section III-F, Exempt Experiments		
Motion:	Modifications Required		
Vote:	**Yes:** 12	**No:** 0	**Abstain:** 0
	Recuse: 0	**Absent:** 0	

PI:	Jeffrey Steimle
Study ID:	IBC2025-0043
Title:	Transcription factor biology of cardiopulmonary development and disease
Biosafety Items:	DAVPM
Action:	New
Primary Reviewer:	Stephen Waggoner
Secondary Reviewer:	Ian Lewkowich
Agents:	293T HELA AAV Type 9
BSL:	2
Applicable NIH Guidelines:	*Section III-D-4-a* Recombinant or synthetic nucleic acid molecules, or DNA or RNA molecules derived therefrom, from any source except for greater than two-thirds of eukaryotic viral genome may be transferred to any non-human vertebrate or any invertebrate organism and propagated under conditions of physical containment comparable to BL1 or BL1-N and appropriate to the organism under study. Animals that contain sequences from viral vectors, which do not lead to transmissible infection either directly or indirectly as a result of complementation or recombination in animals, may be propagated under conditions of physical containment comparable to BL1 or BL1-N and appropriate to the organism under study *Section III-D-4-c-(1)* Experiments involving the generation of transgenic rodents that require BL1 containment are described under Section III-E-3, Experiments Involving Transgenic Rodents

	Section III-D-4-c-(2) The purchase or transfer of BL1 transgenic rodents is exempt from the NIH Guidelines under Section III-F, Exempt Experiments *Section III-E* Experiments that Require Institutional Biosafety Committee Notice Simultaneous with Initiation *Section III-E-3* Experiments Involving Transgenic Rodents *Section III-F* Exempt Experiments *Section III-F-2* Those that are not in organisms, cells, or viruses and that have not been modified or manipulated (eg, encapsulated into synthetic or natural vehicles) to render them capable of penetrating cellular membranes *Section III-F-8-C-II* Experiments that use Escherichia coli K-12 host-vector systems *Section III-F-8-C-VII* The purchase or transfer of transgenic rodents, BSL1 only *Section III-F-8-C-VIII* Generation of BL1 Transgenic Rodents via Breeding		
Motion:	Modifications Required		
Vote:	**Yes:** 12	**No:** 0	**Abstain:** 0
	Recuse: 0	**Absent:** 0	

PI:	Koichi Araki
Study ID:	IBC2025-0025
Title:	Immunological Memory and Exhaustion
Biosafety Items:	DAVPM
Action:	Renewal
Primary Reviewer:	Bryan Donnelly
Secondary Reviewer:	Buddy Goose
Agents:	Listeria monocytogenes Human Derived Blood and Blood Types 293T HELA VERO-E6 Influenza virus type A (Orthomyxoviruses) Lentivirus Lymphocytic choriomeningitis virus (LCM) (neurotropic strains) (Arenaviruses) Murine leukemia virus (Retrovirus)

	Murine stem cell virus (Retrovirus) Vaccinia virus		
BSL:	2		
Applicable NIH Guidelines:	Experiments that Require Institutional Biosafety Committee Approval Before Initiation *Section III-D-3-a* Experiments involving the use of infectious or defective Risk Group 2 viruses in the presence of a helper system may be conducted at BL2 *Section III-D-3-b* Experiments involving the use of infectious or defective Risk Group 3 viruses in the presence of a helper system may be conducted at BL3 *Section III-D-4-a* Recombinant or synthetic nucleic acid molecules, or DNA or RNA molecules derived therefrom, from any source except for greater than two-thirds of eukaryotic viral genome may be transferred to any non-human vertebrate or any invertebrate organism and propagated under conditions of physical containment comparable to BL1 or BL1-N and appropriate to the organism under study. Animals that contain sequences from viral vectors, which do not lead to transmissible infection either directly or indirectly as a result of complementation or recombination in animals, may be propagated under conditions of physical containment comparable to BL1 or BL1-N and appropriate to the organism under study *Section III-D-4-c-(2)* The purchase or transfer of BL1 transgenic rodents is exempt from the NIH Guidelines under Section III-F, Exempt Experiments *Section III-E* Experiments that Require Institutional Biosafety Committee Notice Simultaneous with Initiation *Section III-E-1* Experiments Involving the Formation of Recombinant or Synthetic Nucleic Acid Molecules Containing No More than Two-Thirds of the Genome of any Eukaryotic Virus *Section III-E-3* Experiments Involving Transgenic Rodents		
Motion:	Modifications Required		
Vote:	**Yes:** 12	**No:** 0	**Abstain:** 0
	Recuse: 0	**Absent:** 0	

PI:	Yueh-Chiang Hu		
Study ID:	IBC2025-0020		
Title:	Study of gonad and muscle development and therapy		
Biosafety Items:	DAM		
Action:	Renewal		
Primary Reviewer:	James Gulick		
Secondary Reviewer:	Brenna Carey		
Agents:	293T Human iPSC Lines		
BSL:	2		
Applicable NIH Guidelines:	Use of recombinant or synthetic nucleic acids in tissue culture. Use of recombinant or synthetic nucleic acids in animals, including use of genetically modified model organisms.		
Motion:	Modifications Required		
Vote:	**Yes:** 12	**No:** 0	**Abstain:** 0
	Recuse: 0	**Absent:** 0	

PI:	John Hoganesch		
Study ID:	IBC2025-0031		
Title:	Cellular, physiological, and behavioral genetics of circadian rhythms		
Biosafety Items:	DAVM		
Action:	Renewal		
Primary Reviewer:	Karnail Singh		
Secondary Reviewer:	James Gulick		
Agents:	Human Derived Blood and Blood Types Saliva 293T HEP-G2 JURKAT MCF-7 U-2 OS Lentivirus		
BSL:	2		
Applicable NIH Guidelines:	Experiments involving the use of infectious or defective Risk Group 3 viruses in the presence of a helper system may be conducted at BL3 Use of recombinant or synthetic nucleic acids in tissue culture. Use of recombinant or synthetic nucleic acids in animals, including use of genetically modified model organisms.		
Motion:	Modifications Required		
Vote:	**Yes:** 12	**No:** 0	**Abstain:** 0

	Recuse: 0	**Absent:** 0

PI:	Anne Slavotinek		
Study ID:	IBC2025-0029		
Title:	Genetic analysis of eye defects and multiple congenital anomaly syndromes		
Biosafety Items:	DAVPM		
Action:	Renewal		
Primary Reviewer:	Sherry Thornton		
Secondary Reviewer:	Bryan Donnelly		
Agents:	Human Derived Blood and Blood Types Saliva 293T Human iPSC Lines Lentivirus		
BSL:	2		
Applicable NIH Guidelines:	Experiments Using Risk Group 2, Risk Group 3, Risk Group 4, or Restricted Agents as Host-Vector Systems Use of recombinant or synthetic nucleic acids in tissue culture. Use of recombinant or synthetic nucleic acids in animals, including use of genetically modified model organisms.		
Motion:	Modifications Required		
Vote:	**Yes:** 12	**No:** 0	**Abstain:** 0
	Recuse: 0	**Absent:** 0	

PI:	James Wells
Study ID:	IBC2025-0017
Title:	Development and Diseases of the Digestive Tract
Biosafety Items:	DAVM
Action:	Renewal
Primary Reviewer:	Brenna Carey
Secondary Reviewer:	Scott Keely
Agents:	H1 H9 HEK293FT Human iPSC Lines Lentivirus
BSL:	2
Applicable NIH Guidelines:	*Section III-D-3-b* Experiments involving the use of infectious or defective Risk Group 3 viruses in the presence of a helper system may be conducted at BL3

	Section III-D-4-a Recombinant or synthetic nucleic acid molecules, or DNA or RNA molecules derived therefrom, from any source except for greater than two-thirds of eukaryotic viral genome may be transferred to any non-human vertebrate or any invertebrate organism and propagated under conditions of physical containment comparable to BL1 or BL1-N and appropriate to the organism under study. Animals that contain sequences from viral vectors, which do not lead to transmissible infection either directly or indirectly as a result of complementation or recombination in animals, may be propagated under conditions of physical containment comparable to BL1 or BL1-N and appropriate to the organism under study *Section III-D-4-c-(2)* The purchase or transfer of BL1 transgenic rodents is exempt from the NIH Guidelines under Section III-F, Exempt Experiments *Section III-E-1* Experiments Involving the Formation of Recombinant or Synthetic Nucleic Acid Molecules Containing No More than Two-Thirds of the Genome of any Eukaryotic Virus *Section III-E-3* Experiments Involving Transgenic Rodents		
Motion:	Modifications Required		
Vote:	**Yes:** 12	**No:** 0	**Abstain:** 0
	Recuse: 0	**Absent:** 0	

Discussion items
None